Novartis leukemia drugs show promise
ZURICH (Reuters) - Novartis AG’s cancer drug Tasigna was effective and helped achieve rapid responses as an initial therapy in newly diagnosed patients with a life threatening form of leukemia, the company said.
Data from two mid-stage clinical trials presented at an American Society of Hematology meeting showed there was rapid elimination of cancer cells in 96 percent of Tasigna patients with Philadelphia chromosome-positive chronic myeloid leukemia
(CML).
“Tasigna now shows potential to become the treatment of choice for certain newly diagnosed patients with chronic myeloid leukemia,” Novartis said in a statement.
Tasigna is approved in CML in patients who no longer respond to Glivec, currently Novartis’s second-biggest seller.
Separate data presented on Monday showed nearly nine out of ten patients with CML are still alive after seven years of a late-stage clinical trial with Glivec.
It is the longest overall survival observed for patients with Philadelphia chromosome-positive CML, a life-threatening form of the disease, data from a late-stage trial presented at the meeting showed.
CML is a cancer of the blood and bone marrow in which the body produces cancerous white blood cells.
Almost all patients with CML have an abnormality known as the Philadelphia chromosome, which produces a protein that causes malignant white blood cells to proliferate.
(Reporting by Sam Cage; Editing by Victoria Bryan)
--------------------------------------------------------------------------------------------Related Posts:
LOS ANGELES (Reuters) - A combination of Genentech Inc’s cancer drug Rituxan and chemotherapy reduces by 41 percent the risk of death or cancer progression, compared with chemotherapy alone, for patients with a common form of leukemia, the company said on Saturday. Results from the pivotal- or final-stage trial found that previously untreated patients given the
Full Post: Genentech drug boosts leukemia patient survival
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - Research from Italy provides new evidence that exposure to the industrial solvent benzene increases a person’s risk of developing multiple myeloma. Dr. Adele Seniori Constantini of the Center for Study and Prevention of Cancer and her colleagues also found an increased risk of chronic lymphoid leukemia with benzene exposure. Two other
Full Post: New study backs solvent, leukemia link
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - U.S. health regulators have approved Novartis’ drug Gleevac to reduce the risk of cancer recurring in patients with a rare type of stomach cancer, Novartis said on Friday. Gleevac is already approved by the Food and Drug Administration to treat gastrointestinal stromal tumor, a severe type of cancer that recurs in as many
Full Post: U.S. OKs Novartis Gleevac to reduce recurring cancer
--------------------------------------------------------------------------------------------
By Julie Steenhuysen CHICAGO (Reuters) - Leukemia cells use powerful chemical signals to lure healthy blood-forming stem cells into their cancerous lairs, where they lose their power to make healthy blood cells, U.S. researchers said on Thursday. But by jamming these signals in mice, the team was able to protect the stem cells, called hematopoietic progenitor cells. If
Full Post: Fatal attraction: How leukemia seduces blood cells
--------------------------------------------------------------------------------------------
ZURICH (Reuters) - Novartis AG’s Tekturna reduced blood pressure in patients aged 65 and over by significantly more than the older drug ramipril, the Swiss drugmaker said on Tuesday. Data showed that Tekturna — known as Rasilez in Europe — gave an additional reduction in systolic blood pressure of 2.3 millimeters of mercury (mmHG) compared with
Full Post: Tekturna works better in older patients: Novartis